Targeted degradation of hexokinase 2 by a novel engineered bispecific chimeric liposome-based Nano-PROTACs for enhancing tumor chemotherapy
- 27 August 2025
- journal article
- Published by Elsevier in Biomaterials
- Vol. 326, 123651
Abstract
No abstract availableKeywords
Funding Information
- Shaanxi Key Science and Technology Innovation Team Project (2023-CX-TD-72)
- Natural Science Basic Research Program of Shaanxi Province (2025JC-YBQN-1051)
- Shenzhen Science and Technology Innovation Program (JCYJ20230807145605011)
- National Natural Science Foundation of China (82003691)
- Tailhook Association
- Key Research and Development Projects of Shaanxi Province (2023-YBSF-121)
This publication has 44 references indexed in Scilit:
- Deformable nanocarriers for enhanced drug delivery and cancer therapyExploration, 2024
- The potential of PCNA inhibition as a therapeutic strategy in cervical cancerJournal of Medical Virology, 2023
- Targeted protein delivery based on stimuli‐triggered nanomedicineExploration, 2023
- Metabolic reprogramming and interventions in endometrial carcinomaBiomedicine & Pharmacotherapy, 2023
- Targeted Degradation of PD‐L1 and Activation of the STING Pathway by Carbon‐Dot‐Based PROTACs for Cancer ImmunotherapyAngewandte Chemie International Edition, 2023
- Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 2Cancer Communications, 2023
- Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In VivoAngewandte Chemie International Edition, 2022
- Self-propelled nanomotor reconstructs tumor microenvironment through synergistic hypoxia alleviation and glycolysis inhibition for promoted anti-metastasisActa Pharmaceutica Sinica B, 2021
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological DiscoveryCell, 2020
- Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathwaysBiomaterials, 2013